NeoGenomics is like the LabCorp or Quest Diagnostics specifically for advanced cancer testing.

Think of NeoGenomics as a 'forensic lab' for cancer, uncovering critical biological clues for doctors and drug developers.

• Cytogenetics Testing: Services that study normal and abnormal chromosomes and their relationship to diseases.
• Fluorescence In-Situ Hybridization (FISH) Testing: Services for detecting and locating specific DNA sequences and genes on chromosomes.
• Flow Cytometry Testing: Services that measure the characteristics of cell populations for diagnostic purposes.
• Immunohistochemistry (IHC) & Digital Imaging: Services to localize cellular proteins in tissue sections, along with digital slide visualization and quantitative analysis.
• Molecular Testing: Services focused on the analysis of DNA/RNA and the structure and function of genes at the molecular level.
• Morphologic Analysis: Pathologist-led analysis of cells under a microscope for diagnostic purposes.
• Anatomic Pathology Reference Services: Comprehensive anatomic pathology testing services provided as a reference laboratory.
• Pharmaceutical Oncology Support Services: Testing and support services for pharmaceutical clients' oncology programs, spanning discovery through commercialization.

NeoGenomics (NEO) sells primarily to other companies and organizations, rather than directly to individuals. Based on the provided description, its major customers fall into the following categories:

• Hospitals
• Reference labs
• Pathologists
• Oncologists
• Clinicians
• Pharmaceutical firms
• Researchers

Major Suppliers:

• Roche (RHHBY)
• Thermo Fisher Scientific (TMO)
• Abbott Laboratories (ABT)

Tony Zook, Chief Executive Officer

Tony Zook became CEO of NeoGenomics in April 2025. Prior to his appointment as CEO, he served on NeoGenomics' Board of Directors for two years, chairing the Compensation Committee and serving on the Audit and Technology committees. He brings extensive experience as a brand and marketing executive, focusing on the intersection of commercial and research and development within organizations. Previously, Mr. Zook was the Chief Executive Officer of Innocoll Biotherapeutics. He also held the role of Executive Vice President, Commercial Operations at AstraZeneca (AZ), where he was responsible for global profit and loss for all of AZ's brands and markets, overseeing the commercialization of 10 brands, each exceeding $1 billion in sales. At AZ, he was also responsible for MedImmune, the global biologics business, and chaired the Commercial Investment Board. Earlier in his career at AZ, he held positions including CEO of North America and VP of Sales, and was involved in the integrations of Astra US, Astra Merck, and Zeneca. Mr. Zook spent 14 years with Berlex Laboratories in various roles.

Abhishek Jain, Chief Financial Officer

Abhishek Jain joined NeoGenomics as Executive Vice President on January 12, 2026, and officially transitioned to Chief Financial Officer on March 2, 2026. He possesses over 25 years of global finance and operational leadership experience across the life sciences and diagnostics sectors. Most recently, he served as Chief Financial Officer at CareDx from September 2022 to August 2025, where he was instrumental in guiding the company back to profitable growth, enhancing financial discipline, and strategically allocating resources for long-term value creation. Prior to CareDx, Mr. Jain spent nearly two decades at Agilent Technologies, progressing through various global finance and operational leadership positions. His roles at Agilent included Global Controller for the company's sales and marketing organization, managing a $5 billion orders portfolio, and Head of Agilent Corporate. Mr. Jain is a Certified Public Accountant (inactive) and a Chartered Accountant from the Institute of Chartered Accountants of India.

Warren Stone, President and Chief Operating Officer

Warren Stone was appointed President and Chief Operating Officer of NeoGenomics in April 2025. He joined the company in November 2022 as President, Clinical Services, and was later promoted to Chief Commercial Officer in April 2024. Mr. Stone is recognized as a highly accomplished enterprise leader with extensive global experience in the life science and diagnostic sectors. Before joining NeoGenomics, he served as President of Americas at Ortho Clinical Diagnostics (now QuidelOrtho) and as Senior Vice President at MilliporeSigma. He has over 25 years of experience in general management and cross-functional commercial roles.

Elizabeth Floegel, Chief Digital and Information Officer

Elizabeth Floegel serves as the Chief Digital and Information Officer at NeoGenomics. She brings significant experience in leading digital transformation and technology innovation within the healthcare industry. In her role, Ms. Floegel is crucial in advancing NeoGenomics' digital strategy, utilizing AI and automation to enhance operational efficiency and improve outcomes. Prior to her current position, she was a member of NeoGenomics' Board of Directors, where she served on the Audit and Compliance Committees.

Gary Passman, Chief Culture Officer

Gary Passman is the Chief Culture Officer at NeoGenomics, where he is responsible for the company's strategy concerning its people and fostering an engaging culture that supports all teammates and customers. He holds a Bachelor of Arts in economics and a Master's degree in human resource management from Rutgers University. Mr. Passman joined NeoGenomics in 2008 as Director of Human Resources, was appointed Vice President, Human Resources in 2015, and became Chief Culture Officer in 2016.

The key risks to NeoGenomics (NEO) include:

1. Financial Health and Profitability Challenges: NeoGenomics is currently operating at a loss, with declining gross margins and inconsistent revenue growth over the past five years. The company's Altman Z-Score also indicates a potential risk of financial distress. High debt levels further increase financial risk, as the company's debt exceeds its cash on the balance sheet. This ongoing unprofitability and financial pressure can limit the company's ability to invest in growth initiatives.
2. Intense Competition and Technology Adoption: The oncology diagnostic market is highly competitive and rapidly evolving, particularly in next-generation sequencing (NGS) and liquid biopsy. NeoGenomics faces significant competition from well-established players and emerging companies like Guardant Health and Natera, who possess large financial resources and aggressive sales strategies. The company has previously faced challenges in offering the most technologically advanced NGS tests, which led to a decrease in revenue as customers sought testing elsewhere. Continuous innovation and successful commercialization of new products, such as the RaDaR ST assay, are crucial to maintain and gain market share.
3. Regulatory and Reimbursement Risks: As a company in the healthcare sector, NeoGenomics is subject to a complex and evolving regulatory environment, particularly concerning Laboratory Developed Tests (LDTs). Changes in regulations could impact the company's operations and test offerings. Furthermore, the process of obtaining and maintaining adequate reimbursement for specialized molecular diagnostic panels can be challenging, leading to payment bottlenecks, delays, or lower-than-expected payments from insurers and Medicare. While NeoGenomics recently secured Medicare coverage for its PanTracer LBx test, the broader risk of reimbursement complexities remains a significant factor influencing revenue and profitability.

NeoGenomics, Inc. operates in several significant addressable markets within cancer diagnostics across the globe and specifically in the U.S.

Oncology Molecular Diagnostics (including Molecular Testing)

• The global oncology molecular diagnostics market size is projected to reach approximately USD 7.11 billion by 2034. Another estimate places the global market at around USD 10.93 billion by 2035, growing from USD 3.90 billion in 2026.
• In 2024, the global oncology molecular diagnostics market was valued at USD 3.75 billion, with projections to reach USD 6.35 billion by 2030.
• The U.S. oncology molecular diagnostics market is anticipated to grow from USD 810 million in 2024 to USD 2.57 billion by 2034.
• North America is a dominant region in the global oncology molecular diagnostics market, holding a 44.69% revenue share in 2024.

Immunohistochemistry (IHC) Testing

• The global immunohistochemistry market size was estimated at USD 2.40 billion in 2024 and is projected to reach USD 3.50 billion by 2030.
• Other estimates for the global market size include USD 4.11 billion by 2033 and USD 5.11 billion by 2030, growing from USD 3.55 billion in 2025.
• North America held the largest revenue share in the global immunohistochemistry market in 2024, with over 37.77%.

Flow Cytometry Testing

• The global flow cytometry market size was estimated at USD 4.68 billion in 2024 and is projected to reach USD 7.01 billion by 2030.
• Another report values the global market at USD 6.40 billion in 2024, expected to reach USD 14.71 billion by 2032.
• North America dominated the flow cytometry market in 2024 with a 41.35% revenue share.

Molecular Cytogenetics (including Cytogenetics and FISH Testing)

• The global molecular cytogenetics market size was estimated at USD 2.40 billion in 2024 and is projected to reach USD 6.39 billion by 2033.
• The global molecular cytogenetics market is also projected to grow from USD 1.78 billion in 2026 to USD 3.67 billion by 2034.
• North America held the dominant share of the global molecular cytogenetics market in 2024. The U.S. market is estimated to reach USD 0.64 billion in 2026.

Fluorescence In Situ Hybridization (FISH) Testing

• The global fluorescent in situ hybridization (FISH) market size was valued at USD 1.14 billion in 2024 and is expected to reach USD 2.14 billion by 2032.
• The global molecular FISH testing market was valued at US$ 731.4 million in 2023 and is projected to hit US$ 1.37 billion by 2032.
• The global market for FISH in cancer diagnostics is anticipated to reach USD 2.5 billion by 2025.

Solid Tumor MRD (Minimal Residual Disease) Cancer Monitoring

• NeoGenomics is entering a rapidly growing solid tumor MRD cancer monitoring market, which is estimated to be over $20 billion.

Overall Cancer Diagnostics Market

• The global cancer diagnostics market size was valued at USD 17.24 billion in 2025 and is projected to grow to USD 38.27 billion by 2034.
• Another estimate places the global cancer diagnostics market size at USD 110.11 billion in 2024, expected to reach USD 199.32 billion by 2032.
• North America held the largest share of the global cancer diagnostics market in 2025, at 36.81%.

Cancer-focused Genetic Testing Services

• The global cancer-focused genetic testing service market size is likely to reach USD 8.47 billion by 2024 and is projected to reach USD 19.3 billion by the end of 2034.
• The global market size was valued at USD 7.78 billion in 2023 and is expected to exceed USD 16.51 billion by 2033.

NeoGenomics (NASDAQ: NEO) anticipates several key drivers to fuel its revenue growth over the next 2-3 years:

1. New Product Launches and Adoption: The company expects significant revenue growth from the full clinical launch and adoption of its RaDaR ST minimal residual disease (MRD) assay, particularly from 2027 onwards, addressing a rapidly growing market. Additionally, the continued adoption of the PanTracer family (Tissue, Liquid, Pro) for therapy selection is projected to be a key contributor to growth.
2. Increased Adoption of High-Value Clinical Testing: NeoGenomics is strategically shifting its focus towards higher-value, therapy-guided testing, including Next-Generation Sequencing (NGS), which has demonstrated strong growth rates (23% in Q4 2025 and 22% for full-year 2025). This shift is expected to drive Average Unit Price (AUP) expansion, which management forecasts as the primary revenue driver.
3. Sales Force Expansion: To support the uptake of new products and indications, NeoGenomics plans to expand its sales force from 140 to approximately 165 representatives by the end of the year.
4. Payer Coverage Expansion and Reimbursement Initiatives: Securing timely reimbursement approvals, especially MolDX coverage for PanTracer Liquid and broader RaDaR indications, is critical for sustained momentum. The company's strategic reimbursement initiatives and managed care pricing increases are already contributing to higher average revenue per clinical test.
5. Operational Efficiencies and Technology Upgrades: Benefits from the implementation of a single Laboratory Information Management System (LIMS) are anticipated to become more pronounced in 2027 and 2028. Furthermore, the utilization of automation and artificial intelligence (AI) is expected to enhance operational efficiencies and contribute to gross margin expansion.

Outbound Investments

• NeoGenomics completed the acquisition of Pathline, LLC in March 2025, expanding its commercial presence in the Northeast U.S. and enhancing its oncology testing services, particularly in molecular and hematology-oncology testing.
• In January 2020, NeoGenomics acquired the Oncology Division assets of Human Longevity, Inc. for $37 million, which significantly enhanced its Next Generation Sequencing capabilities for pharmaceutical customers.
• NeoGenomics has a history of growth through acquisitions, with 2 acquisitions in 2021 and an average of 0.6 acquisitions per year between 2020 and 2025.

Inbound Investments

• Institutional investors have made significant investments, with FIRST LIGHT ASSET MANAGEMENT, LLC adding over 3 million shares in Q3 2025 (estimated at $23.78 million) and MILLENNIUM MANAGEMENT LLC adding over 2.6 million shares in Q3 2025 (estimated at $20.5 million).
• BlackRock, Inc. held a substantial stake in NeoGenomics as of late 2025.

Capital Expenditures

• Capital expenditures were approximately $27 million in 2025, $41 million in 2024, $29 million in 2023, and $19 million in 2022.
• In the most recent 12 months, capital expenditures were -$27.01 million.
• The company's capital expenditures in the most recent quarter totaled -$8.31 million.